Dapoflit Trio 1-1000 Tablet is a powerful triple-drug oral formulation combining Dapagliflozin 10mg, Glimepiride 1mg, and Metformin 1000mg, developed for comprehensive management of type-2 diabetes mellitus. This combination addresses insulin resistance, impaired insulin secretion, and excess glucose production to deliver effective and sustained glycemic control.
Dapagliflozin facilitates renal glucose excretion, Glimepiride enhances pancreatic insulin release, and Metformin reduces hepatic glucose output while improving peripheral insulin sensitivity. Together, these mechanisms ensure optimal control of both fasting and post-prandial blood glucose levels in patients requiring intensified therapy.
Clinically, this combination is widely prescribed by diabetologists, physicians, and endocrinologists for patients inadequately controlled on dual therapy. Its high-strength Metformin base makes it particularly suitable for patients with higher insulin resistance and long-standing diabetes.
From a commercial standpoint, Dapoflit GM 1000 Tablet strengthens your anti-diabetic and metabolic-care segment, creating strong opportunities in hospital supply, chronic-care clinics, pharmacy distribution, institutional procurement, export markets, and third-party manufacturing. Its triple-mechanism action and high prescription demand make it a stable, high-value product for pharmaceutical distribution.